Clinical Trial Update: GSK239512 DDI Study [Phase 1]

View source ↗

Summary

Phase 1 study evaluating drug-drug interactions for GSK239512 in people with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GSK239512 (GSK239512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED